Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC
项目 2:靶向 MERTK 改善 EGFR 突变 NSCLC 的预后
基本信息
- 批准号:10685418
- 负责人:
- 金额:$ 35.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-10 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:ABCG2 geneAddressAftercareAnimal ModelBindingBiological MarkersBiopsyBiopsy SpecimenBloodBlood specimenBone MarrowCancer EtiologyCancer ModelCancer PatientCaringCell Culture TechniquesCell LineCellsCessation of lifeClinicalClinical ResearchClinical TrialsCollectionCorrelative StudyCytotoxic ChemotherapyDataDedicationsDevelopmentDoseEGFR inhibitionEnrollmentEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorFDA approvedFamilyGenerationsGeneticGuidelinesHumanImmuneImmune responseImmune systemImmunologic MarkersImmunosuppressionImplantInnate Immune ResponseInternationalKnock-outKnockout MiceLigandsLungMERTK geneMalignant NeoplasmsMalignant neoplasm of lungMediatingMediatorModelingMonitorMulticenter StudiesMusMutateMutationNational Comprehensive Cancer NetworkNatural ImmunityNeoplasm MetastasisNew AgentsNewly DiagnosedNon-Small-Cell Lung CarcinomaOncogenicPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacodynamicsPhasePhase Ib Clinical TrialPhenotypePhosphorylationPrognosisQuality of lifeReceptor Protein-Tyrosine KinasesRecombinantsRecommendationResearch PersonnelResistanceResistance developmentRoleSafetySamplingSignal TransductionTestingTherapeuticTherapeutic EffectTranslatingTumor ImmunityTumor-associated macrophagesTyrosine Kinase InhibitorUniversitiescell killingchemokineclinical applicationcohortcytokinecytotoxicfirst-in-humanimmune cell infiltrateimmune functionimprovedimproved outcomeinhibitorinhibitor therapykinase inhibitorlung cancer cellmouse modelmutantmutational statusneoplastic cellnovelnovel strategiespatient derived xenograft modelpatient responsepermissivenesspharmacodynamic biomarkerpotential biomarkerpre-clinicalpreclinical studyprogramsresistance mechanismresistance mutationresponse biomarkersmall hairpin RNAsubcutaneoustargeted treatmenttherapeutic targettumortumor growthtumor microenvironmenttumorigenesis
项目摘要
Summary/Abstract:
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related death in the US.
EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes for patients who have non-small cell lung cancer
(NSCLC) with an activating EGFR mutation (EGFRMT), but many tumors do not respond and most that do will
become resistant in 9-12 months. Osimertinib, a 3rd generation EGFR TKI, has recently advanced to frontline
therapy for EGFRMT NSCLC, irrespective of T790M mutation, but treatment options remain limited for patients
who develop resistant tumors. This proposal describes preclinical studies to evaluate inhibition of the MERTK
receptor tyrosine kinase in combination with EGFR TKIs for treatment of EGFRMT NSCLC and includes a phase
1b clinical trial to test the combination in these patients. 70% of NSCLCs have abnormally high levels of MERTK
and inhibition in tumor cells decreases tumor growth in mice. MERTK is also present in immune cells in the tumor
microenvironment, where it suppresses the anti-tumor innate immune response. Our data suggest that inhibition
of MERTK reprograms the immune system to attack the tumor. MERTK can also mediate resistance to EGFR
TKIs, including osimertinib, suggesting that MERTK inhibition will sensitize EGFRMT tumors to treatment with
EGFR TKIs and may decrease development of resistance. These data identify MERTK as a new target in NSCLC
and implicate MERTK-targeted inhibitors as an unprecedented opportunity to provide a three-pronged
therapeutic approach in a single drug, leading to (1) direct tumor cell killing, (2) activation of anti-tumor innate
immunity, and (3) increased sensitivity to EGFR TKI therapy. To test this idea and generate drugs that can be
used in humans, we developed MERTK-selective TKIs, including MRX-2843. MRX-2843 is effective as
monotherapy in mice and increases sensitivity to EGFR TKIs in EGFRMT NSCLC cells. The proposed studies
use MRX-2843 and other MERTK inhibitors to investigate the effects of combined MERTK and EGFR inhibition
in cell culture and mouse models of EGFRMT NSCLC, including models with tumor cells implanted directly in the
lung, models derived from fresh patient samples, and models of tumor cell metastasis. Mice with mertk knock-
out will also be used to determine the effects of MERTK inhibition in the tumor microenvironment and its impact
on anti-tumor immunity. Additional studies will determine how MERTK inhibition in the immune system leads to
tumor rejection. Finally, a highlight of this project is the dedicated clinical trial of MRX-2843 and osimertinib in
patients with advanced EGFRMT NSCLC, a study that includes 2 expansion cohorts with paired collection of pre-
and post-treatment tumor biopsies and blood samples to evaluate biomarkers of MERTK inhibition, including
changes in immune function, following treatment with MRX-2843. The results from the clinical trial and
associated studies will provide more effective and less toxic treatment options leading to optimized care and
improved survival for patients with EGFRMT NSCLC.
总结/摘要:
肺癌是全球最常见的癌症,也是美国癌症相关死亡的主要原因。
EGFR酪氨酸激酶抑制剂(TKI)可改善非小细胞肺癌患者的预后
(NSCLC)与激活EGFR突变(EGFRMT),但许多肿瘤不响应,大多数会
在9-12个月内产生耐药性。奥希替尼是第三代EGFR TKI,最近已进入一线治疗
EGFRMT NSCLC治疗,不考虑T790 M突变,但患者的治疗选择仍然有限
会产生抗药性肿瘤本提案描述了评价MERTK抑制的临床前研究
受体酪氨酸激酶联合EGFR TKI治疗EGFRMT NSCLC,包括一个阶段
1b临床试验,以测试这些患者的组合。70%的NSCLC具有异常高水平的MERTK
并且抑制肿瘤细胞降低小鼠中的肿瘤生长。MERTK也存在于肿瘤的免疫细胞中
微环境,在那里它抑制抗肿瘤先天免疫反应。我们的数据表明,
重新编程免疫系统来攻击肿瘤。MERTK也可介导EGFR耐药
TKI,包括奥希替尼,表明MERTK抑制将使EGFRMT肿瘤对以下治疗敏感:
EGFR TKI,并可能减少耐药性的发展。这些数据将MERTK确定为NSCLC的新靶点
并暗示MERTK靶向抑制剂是一个前所未有的机会,
在单一药物中的治疗方法,导致(1)直接杀死肿瘤细胞,(2)激活抗肿瘤先天性
免疫力,和(3)对EGFR TKI治疗的敏感性增加。为了测试这个想法并生产出可以
用于人体时,我们开发了MERTK选择性TKI,包括MRX-2843。MRX-2843有效,
在小鼠中进行单药治疗,并增加EGFRMT NSCLC细胞对EGFR TKI的敏感性。拟议的研究
使用MRX-2843和其他MERTK抑制剂研究MERTK和EGFR联合抑制的影响
在EGFRMT NSCLC的细胞培养物和小鼠模型中,包括肿瘤细胞直接植入
肺、来源于新鲜患者样品的模型和肿瘤细胞转移的模型。mertk基因敲除的小鼠-
还将用于确定MERTK抑制在肿瘤微环境中的作用及其影响
对抗肿瘤免疫的影响。其他研究将确定免疫系统中的MERTK抑制如何导致
肿瘤排斥最后,该项目的一个亮点是MRX-2843和奥希替尼在
晚期EGFRMT NSCLC患者,一项包括2个扩展队列的研究,
以及治疗后肿瘤活检和血液样本,以评价MERTK抑制的生物标志物,包括
MRX-2843给药后免疫功能的变化。临床试验的结果和
相关研究将提供更有效和毒性更小的治疗选择,从而优化护理,
改善EGFRMT NSCLC患者的生存率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DOUGLAS K GRAHAM其他文献
DOUGLAS K GRAHAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DOUGLAS K GRAHAM', 18)}}的其他基金
Novel TYRO3 inhibitors for treatment of cancer
用于治疗癌症的新型 TYRO3 抑制剂
- 批准号:
10182743 - 财政年份:2021
- 资助金额:
$ 35.45万 - 项目类别:
Novel TYRO3 inhibitors for treatment of cancer
用于治疗癌症的新型 TYRO3 抑制剂
- 批准号:
10582629 - 财政年份:2021
- 资助金额:
$ 35.45万 - 项目类别:
Novel TYRO3 inhibitors for treatment of cancer
用于治疗癌症的新型 TYRO3 抑制剂
- 批准号:
10381542 - 财政年份:2021
- 资助金额:
$ 35.45万 - 项目类别:
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity
MERTK/AXL双重抑制剂通过靶向肿瘤细胞并激活抗肿瘤免疫为癌症提供新的治疗方法
- 批准号:
10373031 - 财政年份:2020
- 资助金额:
$ 35.45万 - 项目类别:
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity
MERTK/AXL双重抑制剂通过靶向肿瘤细胞并激活抗肿瘤免疫为癌症提供新的治疗方法
- 批准号:
10589107 - 财政年份:2020
- 资助金额:
$ 35.45万 - 项目类别:
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC
项目 2:靶向 MERTK 改善 EGFR 突变 NSCLC 的预后
- 批准号:
10210199 - 财政年份:2019
- 资助金额:
$ 35.45万 - 项目类别:
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC
项目 2:靶向 MERTK 改善 EGFR 突变 NSCLC 的预后
- 批准号:
10459441 - 财政年份:2019
- 资助金额:
$ 35.45万 - 项目类别:
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin
针对 Mer 和 Axl 受体酪氨酸激酶的新型生物靶向疗法
- 批准号:
8118019 - 财政年份:2010
- 资助金额:
$ 35.45万 - 项目类别:
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin
针对 Mer 和 Axl 受体酪氨酸激酶的新型生物靶向疗法
- 批准号:
8267692 - 财政年份:2010
- 资助金额:
$ 35.45万 - 项目类别:
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin
针对 Mer 和 Axl 受体酪氨酸激酶的新型生物靶向疗法
- 批准号:
7992763 - 财政年份:2010
- 资助金额:
$ 35.45万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.45万 - 项目类别:
Research Grant